Recent advances: Oncology
- 13 February 1999
- Vol. 318 (7181) , 445-448
- https://doi.org/10.1136/bmj.318.7181.445
Abstract
Cancer is an increasing cause of morbidity and mortality in most countries. It has recently overtaken heart disease as the commonest cause of death in the United Kingdom. “Breakthroughs” in cancer research are reported regularly in the media. Some reports are based on new results that show potential for improved treatments, but others are premature or publicity seeking, and the motivation behind them is questionable. The public has high expectations that basic science cancer research will translate into improved cancer cures and care. Yet awareness and understanding of the clinical trials that are essential in establishing the effectiveness of new treatments is limited. Recruitment to randomised clinical trials evaluating new cancer treatments is often slow, partly because people are convinced that all new treatments are likely to be an improvement and partly because of unease about the process of randomisation. Better public education about categories of evidence in relation to health interventions might contribute to speedier and more appropriate evaluation of promising treatments. Public confidence that cancer care in the United Kingdom is optimal has been shaken by reports that outcomes for some common cancers differ in countries in western Europe, and that survival rates in Britain for 18of 25cancer types studied are poorer than in most other European countries. 1 2 Better than average outcomes were seen in Switzerland, Finland, and Holland. These reports, together with evidence that cancer survival rates differ within a country according to the pattern of care, prompted review of the provision of care for cancer patients in the United Kingdom and in parts of Australia.3–6 Optimal organisation of cancer care might achieve appreciable gains. In the case of breast cancer, this could amount to a 5% improvement in the survival rate at five years. Such a gain would be viewed as …Keywords
This publication has 30 references indexed in Scilit:
- Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studiesBMJ, 1997
- Use of bisphosphonates in cancer patientsCancer Treatment Reviews, 1996
- On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993Annals of Oncology, 1996
- The importance of a multidisciplinary group in the treatment of soft tissue sarcomasEuropean Journal Of Cancer, 1996
- Gene Transfer as Cancer TherapyPublished by Elsevier ,1995
- Conducting clinical research in the new NHS: the model of cancerBMJ, 1994
- Chemotherapy for Colorectal CancerNew England Journal of Medicine, 1994
- Radiotherapy for bone pain: Is a single fraction good enoughClinical Oncology, 1994
- Treatment outcome in a multidisciplinary cancer pain clinicPain, 1991
- Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival.BMJ, 1991